Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding

[1]  R. Jalan,et al.  Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. , 2015, Journal of hepatology.

[2]  Nahia Ezkurdia,et al.  The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[3]  M. Naldi,et al.  Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis , 2014, Hepatology.

[4]  K. Massey,et al.  Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 , 2014, Nature Medicine.

[5]  J. Sánchez-Delgado,et al.  Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. , 2013, Journal of hepatology.

[6]  R. Jalan,et al.  Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications , 2013, Hepatology.

[7]  D. Thabut,et al.  Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. , 2013, JAMA.

[8]  B. Runyon,et al.  Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 , 2013, Hepatology.

[9]  A. Bhalla,et al.  Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study , 2013, The American Journal of Gastroenterology.

[10]  Antonio Gasbarrini,et al.  Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial , 2013, Hepatology.

[11]  S. Ladas,et al.  Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis , 2013, Journal of gastroenterology and hepatology.

[12]  R. Navickis,et al.  Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[14]  Nahia Ezkurdia,et al.  Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats , 2012, Hepatology.

[15]  B. Procopet,et al.  Letter: sorafenib in portal hypertension , 2012, Alimentary pharmacology & therapeutics.

[16]  A. Krag,et al.  Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia , 2012, Alimentary pharmacology & therapeutics.

[17]  M. Pavesi,et al.  Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. , 2012, Journal of hepatology.

[18]  O. Yokosuka,et al.  Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding , 2012, Scandinavian journal of gastroenterology.

[19]  P. Caraceni,et al.  Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials , 2012, Hepatology.

[20]  W. Koizumi,et al.  Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study , 2012, Journal of Gastroenterology.

[21]  A. Bhalla,et al.  Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. , 2012, Journal of hepatology.

[22]  T. Reiberger,et al.  The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study , 2012, Alimentary pharmacology & therapeutics.

[23]  A. Gerbes,et al.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity , 2011, Gut.

[24]  O. Mir,et al.  Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib , 2011, PloS one.

[25]  S. D. Lee,et al.  Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial , 2010, Gut.

[26]  D. Thabut,et al.  Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. , 2010, Gastroenterology.

[27]  M. Mitterhauser,et al.  Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.

[28]  S. Raptis,et al.  Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[29]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.

[30]  Jaume Bosch,et al.  Angiogenesis in liver disease. , 2009, Journal of hepatology.

[31]  Jeffrey S. Morris,et al.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[33]  M. Mejías,et al.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.

[34]  J. Meunier,et al.  Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system , 2006, Hepatology.

[35]  F. Nevens,et al.  Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure , 2006, Critical care.

[36]  Y. Mahida,et al.  A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis , 2004, Alimentary pharmacology & therapeutics.

[37]  G. Jennings,et al.  The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis , 2003, Annals of Internal Medicine.

[38]  R. Terg,et al.  Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study , 2003, Hepatology.

[39]  J. Calleja,et al.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement , 2003, Hepatology.

[40]  T. Reynolds,et al.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[41]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[42]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[43]  C. Sabin,et al.  Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.

[44]  R. Moreau,et al.  Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. , 1996, Clinical science.

[45]  L. Blendis,et al.  Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.

[46]  P. Pizcueta,et al.  Effects of low‐sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis , 1994, Hepatology.

[47]  R. Moreau,et al.  Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites , 1992 .

[48]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[49]  J. Bosch,et al.  Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. , 1992, Gastroenterology.

[50]  R. Moreau,et al.  Hemodynamic effects of a clonidine‐induced decrease in sympathetic tone in patients with cirrhosis , 1987, Hepatology.

[51]  J. Bruix,et al.  Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. , 1987, Journal of hepatology.